PTC shares soar after SMA drug data impresses marketAfter failing three times to bring their Duchenne therapy to the US market, PTC Therapeutics might be on Share XPTC shares soar after SMA drug data impresses markethttps://pharmaphorum.com/news/ptc-therapeutics-posts-solid-sma-data/
